Tengion(OTC) TNGNQ

Tengion, Inc. is a biotechnology company focused on regenerative medicine, established in 2003 and headquartered in Winston-Salem, North Carolina. The company specializes in the discovery, development, and commercialization of advanced cellular therapeutic products, often referred to as "neo-organs."

Products and Services

• Neo-Kidney Augment aims to improve kidney function in chronic kidney disease patients
• Neo-Urinary Conduit provides an alternative for urinary diversion post-bladder removal
• Intellectual property rights in tissue engineering technology

Growth Outlook

• Regenerative medicine market projected to grow significantly in the coming years
• Increasing demand for innovative therapies in chronic disease management
• Potential partnerships could enhance product development and market reach

Financial Highlights

• Recent quarterly net income reported at -$20.2 million
• Cash and cash equivalents stood at $5.7 million as of September 30, 2014
• Trailing twelve months (TTM) cash flow from operations negative at -$4.3 million

Tengion, Inc. has positioned itself in a rapidly evolving sector of biotechnology, focusing on innovative solutions for organ and tissue regeneration. The company's product pipeline includes promising therapies aimed at addressing significant health challenges, particularly in chronic kidney disease and bladder cancer. The growth outlook remains positive, driven by increasing market demand for regenerative therapies and potential collaborations that could accelerate product development. Financially, the company has faced challenges, as indicated by recent net income losses and negative cash flow from operations. However, the existing cash reserves provide a foundation for ongoing research and development efforts. Investors may find interest in the company's unique approach to regenerative medicine and its potential to capture market share in a growing industry.